Evidence map›Paper›PMID 39746102›Full record

SynthesisPloS one2025

A systematic review to identify research gaps in studies modeling MenB vaccinations against Neisseria infections.

Soeren Metelmann, Alexander Thompson, Anna Donten, Segun Oke, Suzy Sun, Ray Borrow, Feng Xu, Roberto Vivancos, Valerie Decraene, Lorenzo Pellis and 1 more

Abstract readSystematic Review
In one paragraph

Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Soeren MetelmannField Service, UK Health Security Agency, Liverpool, United Kingdom.ORCID 0000-0002-2394-5301
Alexander ThompsonSchool of Health Sciences, Manchester University, Manchester, United Kingdom.
Anna DontenSchool of Health Sciences, Manchester University, Manchester, United Kingdom.
Segun OkeSchool of Mathematics, Manchester University, Manchester, United Kingdom.
Suzy SunBlood Safety, Hepatitis, Sexually Transmitted Infections and HIV Division, UKHSA, London, United Kingdom.
Ray BorrowMeningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Manchester, United Kingdom.
Feng XuSchool of Mathematics, Manchester University, Manchester, United Kingdom.
Roberto VivancosField Service, UK Health Security Agency, Liverpool, United Kingdom.
Valerie DecraeneField Service, UK Health Security Agency, Liverpool, United Kingdom.
Lorenzo PellisSchool of Mathematics, Manchester University, Manchester, United Kingdom.
Ian HallSchool of Mathematics, Manchester University, Manchester, United Kingdom.

Funding

Wellcome Trust
6 · The paper itself

Abstract

The genus Neisseria includes two major human pathogens: N. meningitidis causing bacterial meningitis/septicemia and N. gonorrhoeae causing gonorrhoea. Mathematical models have been used to simulate their transmission and control strategies, and the recent observation of a meningococcal B (MenB) vaccine being partially effective against gonorrhoea has led to an increased modeling interest. Here we conducted a systematic review of the literature, focusing on studies that model vaccination strategies with MenB vaccines against Neisseria incidence and antimicrobial resistance. Using journal, preprint, and grey literature repositories, we identified 52 studies that we reviewed for validity, model approaches and assumptions. Most studies showed a good quality of evidence, and the variety of approaches along with their different modeling angles, was assuring especially for gonorrhoea studies. We identified options for future research, including the combination of both meningococcal and gonococcal infections in studies to have better estimates for vaccine benefits, and the spill over of gonorrhoea infections from the heterosexual to the MSM community and vice versa. Cost-effectiveness studies looking at at-risk and the wider populations can then be used to inform vaccine policies on gonorrhoea, as they have for meningococcal disease.

Indexed as

GonorrheaMeningococcal VaccinesEvidence GapsHumansMeningococcal InfectionsModels, TheoreticalNeisseria gonorrhoeaeNeisseria meningitidis, Serogroup BVaccinationMeningococcal Vaccines

Identifiers

PMID39746102
PMCPMC11694989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.